RxDoctor Payments DataLook up a doctor →

Jaime Burkle, MD

Cardiovascular Disease · Gainesville, GANPI 1326042052

Payments from drug & device makers

$768,761in general payments, 2019–2025

Across 1,120 payments — averaging $686.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$204K
  • Esperion Therapeutics, Inc.$182K
  • Regeneron$154K
  • Boehringer Ingelheim$75K
  • Lilly USA, LLC$48K
  • Pfizer$43K
  • plus $63K from 32 others

What the payments were for

  • Consulting fees$40,3316%
  • Speaking & faculty fees$517,40182%
  • Travel & lodging$49,4668%
  • Food & beverage$20,7613%
  • Education$940%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$768,761 in reported general payments places this provider in the 95th percentile of 640 cardiovascular disease providers in Georgia.

See all cardiovascular disease providers in Georgia

Medicare billing

Part B allowed, 2024
$103,299
Medicare patients
392
Services billed
6,128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Repatha SureclickEvolocumab135$110,289
EliquisApixaban34$35,595
Praluent PenAlirocumab46$34,595
NexlizetBempedoic Acid/Ezetimibe42$21,405
NexletolBempedoic Acid29$19,839
JardianceEmpagliflozin15$19,682
VascepaIcosapent Ethyl26$14,084
Ezetimibe185$2,632
Telmisartan102$1,980
Amlodipine-AtorvastatinAmlodipine/Atorvastatin12$1,706
Rosuvastatin Calcium193$1,625
Metoprolol Succinate64$831
Olmesartan-HydrochlorothiazideOlmesartan/Hydrochlorothiazide24$800
Atorvastatin Calcium62$705
Olmesartan Medoxomil46$631

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Esperion Therapeutics, Inc.Nexlizet, Nexletol$182,495$41,24471 claims
PfizerEliquis$42,817$35,59534 claims
Boehringer IngelheimJardiance$75,076$19,68215 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 640 cardiovascular disease providers in Georgia.

Other cardiovascular disease in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →